Am J Cardiovasc Drugs (2018) 18:109–115 https://doi.org/10.1007/s40256-017-0250-3 ORIGINAL RESEARCH ARTICLE Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease 1 2 3 3 • • • • Stephen J. Nicholls Kausik K. Ray Jan O. Johansson Alan Gordon 3 3 3 3 • • • • Michael Sweeney Chris Halliday Ewelina Kulikowski Norman Wong 1 4 Susan W. Kim Gregory G. Schwartz Published online: 12 October 2017 Springer International Publishing AG 2017 Abstract dyslipidemia, and be undertreated with ß-blocker and anti- Background Inhibition of bromodomain and extra-terminal platelet agents. Treatment with apabetalone produced the (BET) proteins can modulate lipoprotein and inﬂammatory following dose-dependent changes compared with placebo: factors that mediate atherosclerosis. The impact of the BET increases in apolipoprotein A-I (apoA-I) of up to 6.7% inhibitor, apabetalone, on cardiovascular events is unknown. (P \ 0.001), increases in high-density lipoprotein choles- Objective Our objective was to investigate the impact of terol (HDL-C) of up to 6.5% (P \ 0.001), increases in apabetalone on cardiovascular event rates in a pooled large HDL particles of up to 23.3% (P\ 0.001), and analysis of clinical studies in patients with established decreases in
American Journal of Cardiovascular Drugs – Springer Journals
Published: Oct 12, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud